X0306 4 2021-09-15 0 0001347178 Vanda Pharmaceuticals Inc. VNDA 0001785894 Jones Aranthan II C/O VANDA PHARMACEUTICALS INC. 2200 PENNSYLVANIA AVENUE, SUITE 300E WASHINGTON DC 20037 0 1 0 0 Chief Corp. Affairs Officer Common Stock 2021-09-15 4 M 0 4277 12.27 A 90962 D Common Stock 2021-09-15 4 M 0 7842 11.32 A 98804 D Common Stock 2021-09-15 4 S 0 16824 16.488 D 81980 D Employee Stock Option (Right to Buy) 12.27 2021-09-15 4 M 0 4277 0.00 D 2029-07-24 Common Stock 4277 33224 D Employee Stock Option (Right to Buy) 11.32 2021-09-15 4 M 0 7842 0.00 D 2030-02-25 Common Stock 7842 47158 D A portion of the shares was sold to satisfy the exercise price and tax obligations relating to the acquisition of the shares in connection with the stock option exercise. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.40 to $16.605, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. The option vested with respect to 25% of the underlying shares on July 25, 2020, with the remaining 75% of the shares vesting in 36 equal monthly installments beginning August 25, 2020, provided the Reporting Person remains continuously employed by the Issuer through each monthly vesting date. The option vested with respect to 25% of the underlying shares on February 26, 2021, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person remains continuously employed by the Issuer through the applicable vesting date. /s/ Aranthan S. Jones II 2021-09-17